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Abstract
Purpose:  To  study  the  types  of  acquired  restrictive  strabismus  treated  in  a  tertiary  hospital  and
the outcome  of  treatment  with  botulinum  toxin.
Methods:  We  performed  a  10-year  retrospective  study  of  patients  with  restrictive  strabismus
aged ≥18  years  who  were  treated  with  botulinum  toxin.  Treatment  was  considered  successful
if the  ﬁnal  vertical  deviation  was  ≤5  PD,  horizontal  deviation  ≤10  PD,  with  no  head  turn  or
diplopia.
Results: We  included  27  cases  (mean  age,  61.9  years).  Horizontal  strabismus  was  diagnosed  in
11.1%, vertical  in  51.9%,  and  mixed  in  37%.  Strabismus  was  secondary  to  cataract  surgery  in
6 cases,  high  myopia  in  6,  orbital  fractures  in  5,  retinal  surgery  in  5,  Graves  ophthalmopathy
in 4,  and  repair  of  conjunctival  injury  in  1  case.  Diplopia  was  diagnosed  in  all  patients,  head
turn in  33.3%.  The  initial  deviation  was  14  PD  (range,  2--40),  the  mean  number  of  injections
per patient  was  1.6  (range,  1--3),  and  the  mean  dose  was  9.5  IU  (range,  2.5--22.5).  At  the
end of  follow-up,  diplopia  was  recorded  in  59.3%,  head  turn  in  18.5%,  surgical  treatment  in
51.9%, and  need  for  prism  glasses  in  14.8%.  Outcome  was  successful  in  37%  of  patients  (4  high
myopia, 3  orbital  fractures,  2  post-surgical  retinal  detachment,  and  1  post-cataract  surgery).
Mean follow-up  was  3  ±  1.8  years.
Conclusion:  Vertical  deviation  was  observed  in  half  of  the  sample.  The  most  frequent  devia-
tion was  secondary  to  cataract  surgery  and  high  myopia.  Treatment  with  botulinum  toxin  was
successful  in  one-third  of  the  patients  at  the  end  of  follow-up.
© 2016  Spanish  General  Council  of  Optometry.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Please  cite  this  article  in  press  as:  Merino  PS,  et  al.  Botulinum  toxin  for  treatment  of  restrictive  strabismus.  J  Optom.
(2016),  http://dx.doi.org/10.1016/j.optom.2016.09.001
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Resumen
Objetivo:  Estudiar  los  tipos  de  estrabismo  restrictivo  adquirido  tratados  en  un  hospital  terciario,
y los  resultados  del  tratamiento  utilizando  toxina  botulínica.
Métodos:  Realizamos  un  estudio  retrospectivo  de  diez  an˜os  en  pacientes  con  estrabismo  restric-
tivo y  edades  ≥18  an˜os,  a  quienes  se  trató  con  toxina  botulínica.  El  tratamiento  se  consideró
exitoso cuando  la  desviación  vertical  ﬁnal  fue  ≤5  PD,  la  desviación  horizontal  ≤10  PD,  y  no  se
produjo  torsión  ni  diplopía.
Resultados:  Incluimos  27  casos  (edad  media,  61,9  an˜os).  Se  diagnosticó  estrabismo  horizontal
en el  11,1%  de  los  casos,  vertical  en  el  51,9%,  y  mixto  en  el  37%.  El  estrabismo  fue  secundario
a: cirugía  de  cataratas  en  6  casos,  miopía  magna  en  6,  fracturas  orbitales  5,  cirugía  de  la
retina en  5,  oftalmopatía  de  Graves  en  4,  y  reparación  de  lesiones  conjuntivales  en  1  caso.  Se
diagnosticó  diplopía  en  todos  los  pacientes,  y  tortícolis  en  el  33,3%.  La  desviación  inicial  fue
de 14  PD  (rango,  2--40),  el  número  medio  de  inyecciones  por  paciente  fue  de  1,6  (rango,  1-3),
y la  dosis  media  de  9,5  IU  (rango,  2,5-22,5).  Al  ﬁnal  del  seguimiento,  se  registró  diplopía  en
el 59,3%  de  los  casos,  tortícolis  en  el  18,5%,  tratamiento  quirúrgico  en  el  51,9%,  y  necesidad
de gafas  prismadas  en  el  14,8%.  El  resultado  fue  exitoso  en  el  37%  de  los  pacientes  (4  miopes
magnos, 3  fracturas  orbitaria,  2  post-cirugía  de  desprendimiento  de  retina,  y  1  post-cirugía  de
cataratas).  El  seguimiento  medio  fue  de  3  ±  1,8  an˜os.
Conclusión:  Se  observó  desviación  vertical  en  la  mitad  de  la  muestra.  La  desviación  más  fre-
cuente fue  secundaria  a  la  cirugía  de  cataratas  y  a  miopía  magna.  El  tratamiento  con  toxina
botulínica  fue  exitoso  en  una  tercera  parte  de  los  pacientes  al  ﬁnalizar  el  seguimiento.
© 2016  Spanish  General  Council  of  Optometry.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este  es  un
art´ıculo Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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injections  were  not  applied  if  an  increasing  deviation  orntroduction
otulinum  toxin  was  ﬁrst  reported  as  an  alternative  to  stra-
ismus  surgery  in  1980  by  Scott.1 It  can  be  used  to  treat
cquired  restrictive  strabismus  and  proved  to  be  successful
r  at  least  acceptable  for  treatment  of  thyroid  strabismus.2
Most  data  in  the  literature  are  from  isolated  case  reports
r  small  samples  describing  the  effect  of  treatment  with
otulinum  toxin  on  acquired  restrictive  strabismus.3,4 The
ffect  of  botulinum  toxin  has  been  reported  to  be  dimin-
shed  in  this  type  of  strabismus,2 with  a  2-month  duration
f  effect  and  the  need  for  repeat  injections  to  achieve
esults  similar  to  those  achieved  in  comitant  strabismus  and
culomotor  palsy.3 Most  patients  need  surgery  after  admin-
stration  of  botulinum  toxin.2 Results  for  thyroid  strabismus
ave  been  good,  with  a  75%  decrease  in  the  initial  deviation
nd  a  favorable  outcome  in  45.45%  of  cases.3,5 Botulinum
oxin  relaxes  the  inﬂammatory  spasm  that  is  characteris-
ic  of  the  acute  phase  of  the  condition,  although  its  effect
n  the  muscular  ﬁbrosis  and  contracture  that  appear  dur-
ng  the  clinical  course  is  minimal.5 Restrictive  strabismus
econdary  to  orbital  disorders  seems  to  respond  well  to
otulinum  toxin,  especially  in  inﬂammatory  conditions  or
yositis,  although  treatment  has  little  effect  in  orbital  frac-
ures.  The  effect  of  botulinum  toxin  is  independent  of  the
nitial  deviation.6 Other  types  of  restrictive  strabismus  sec-
ndary  to  retinal  detachment  surgery,  cataract  surgery,  and
trabismus  surgery  have  been  treated  with  botulinum  toxin,Please  cite  this  article  in  press  as:  Merino  PS,  et  al.  Botulinum
(2016),  http://dx.doi.org/10.1016/j.optom.2016.09.001
ith  variable  results.7--10
The  beneﬁt  of  botulinum  toxin  in  restrictive  strabismus
s  open  to  debate.  Therapeutic  response  is  associated  with
p
mhe  type  of  deviation  (vertical  or  horizontal),  the  extent
f  deviation,  early  treatment,  age,  and  type  of  restrictive
trabismus.  The  objectives  of  this  study  were  to  describe
he  types  of  acquired  restrictive  strabismus  treated  with
otulinum  toxin  in  a  general  tertiary  hospital  over  a  10-year
eriod  and  analyze  the  outcome  of  treatment.
ubject, material and methods
e  performed  a  retrospective  study  of  patients  aged  ≥18
ears  and  diagnosed  with  acquired  restrictive  strabismus
reated  with  botulinum  toxin  (Botox®, Allergan  Inc.,  Irvine,
A,  USA)  between  January  2002  and  December  2012  in  the
cular  Motility  Section  of  our  hospital.  The  study  was  per-
ormed  in  accordance  with  the  Declaration  of  Helsinki  and
pproved  by  the  Ethics  Committee  of  Hospital  General  Uni-
ersitario  Gregorio  Maran˜ón.
The  inclusion  criterion  was  acquired  restrictive  strabis-
us.  For  the  purposes  of  the  present  study,  restrictive
trabismus  was  deﬁned  as  any  incomitant  deviation  sec-
ndary  to  Graves  ophthalmopathy,  high  myopia,  orbital
onditions,  and  post-surgical  complications  (secondary  to
etinal  detachment  surgery,  cataract  surgery,  and  any  other
cular  surgery),  with  a  positive  forced  duction  test  result
nd  botulinum  toxin  as  the  initial  treatment.  Subsequent toxin  for  treatment  of  restrictive  strabismus.  J  Optom.
atient  objection  were  observed.
The  exclusion  criteria  were  congenital  restrictive  strabis-
us  or  ﬁbrosis  (e.g.,  Duane  syndrome),  infantile  strabismus,
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Botox  and  restrictive  strabismus  
previous  surgery  of  extraocular  muscles,  and  follow-up  of
fewer  than  6  months.
The  data  collected  from  the  patient’s  medical  records
were  age,  sex,  type  of  deviation  (vertical,  horizontal,  or
mixed),  etiology,  diplopia,  head  turn,  extent  of  deviation
in  primary  position  before  treatment,  time  (months)  from
the  onset  of  symptoms  to  the  ﬁrst  injection,  number  of
injections,  total  dose,  and  complications  during  adminis-
tration.  The  other  data  recorded  after  administration  of
botulinum  toxin  were  post-operative  deviation  in  primary
position,  head  turn,  diplopia,  need  for  prism  glasses,  surgi-
cal  treatment,  and  follow-up  from  the  ﬁrst  injection  to  the
end  of  the  study.
Vertical  and  horizontal  deviations  in  primary  position
were  measured  using  the  simultaneous  prism  and  cover  test
at  far  and  near  distance;  the  greatest  deviation  was  used  for
the  statistical  data  analysis.  The  forced  duction  test  was  per-
formed  in  the  operating  room  immediately  before  botulinum
toxin  was  administered.  The  drug  was  always  administered
under  topical  anesthesia  (lidocaine  2%)  with  cardiac  andPlease  cite  this  article  in  press  as:  Merino  PS,  et  al.  Botulinum
(2016),  http://dx.doi.org/10.1016/j.optom.2016.09.001
electromyographic  monitoring  in  the  operating  room  and  an
anesthesiologist  present.
A  successful  outcome  was  considered  to  be  a  vertical
deviation  ≤5  PD,  horizontal  deviation  ≤10  PD,  absence  of
d
a
2
1
Table  1  Pre-treatment  and  post-treatment  data.
Case  Type  Pathology  D/T  Time  until  ﬁrst
injection
(months)asta
No.  of
injections/
dose  (IU)
1  H  HM  Y/Y  6  2/15.0  
2 V  HM  Y/Y  1  2/17.5  
3 M  HM  Y/N  5  1/2.5  
4 H  HM  Y/Y  1  1/2.5  
5 V  HM  Y/N  2  2/10  
6 V  HM  Y/N  1  3/15  
7 V  GO  Y/Y  2  2/10  
8 V  GO  Y/Y  1  1/10  
9 H  GO  Y/N  1  2/10  
10 M  GO  Y/N  1  1/5  
11 M  Post  RD  surg  Y/N  2  1/5  
12 M  Post  RD  surg  Y/N  2  1/5  
13 V  Post  RD  surg  Y/N  1  1/10  
14 M  Post  RD  surg  Y/N  4  1/7.5  
15 V  Post  RD  surg  Y/N  1  3/16  
16 M  Fx  Y/Y  1.5  2/10  
17 M  Fx  Y/Y  1  1/10  
18 V  Fx  Y/N  3  1/10  
19 M  Fx  Y/N  2  1/5  
20 V  Fx  Y/Y  1  3/22.5  
21 V  Post  cat  surg  Y/N  1  1/3  
22 V  Post  cat  surg  Y/N  2  1/4  
23 M  Post  cat  surg  Y/N  1  3/15  
24 M  Post  cat  surg  Y/Y  2  1/10  
25 V  Post  cat  surg  Y/N  1  1/7.5  
26 V  Post  cat  surg  Y/N  2  2/10  
27 V  Post  conj  surg  Y/N  3  2/10  
Type: strabismus type; V: vertical; H: horizontal; M: mixed; HM: high m
surg: post-retinal detachment surgery; post cat surg: post-cataract surg
surgery; D: diplopia; T: torticollis; Y: yes; N: no; PP: primary position; S
glasses after treatment with botulinum toxin; IU: international units. PRESS
3
iplopia  and  head  turn  at  the  end  of  follow-up,  with  no
eed  for  additional  treatment  (prism  glasses  or  surgery).
 descriptive  analysis  was  performed  using  IBM  SPSS
tatistics  for  Windows  Version  22.0  (IBM  Corp,  Armonk,  New
ork,  USA).
esults
 total  of  27  cases  were  included  in  the  study.  The  mean  age
f  the  sample  was  61.9  ±  15.6  years  (range,  29--83  years),
nd  52%  were  women  (14/27).  As  for  diagnosis,  51.9%  had
ertical  restrictive  deviation,  37%  mixed  vertical  and  hori-
ontal  deviation,  and  11.1%  horizontal  deviation.  Strabismus
as  secondary  to  cataract  surgery  with  sub-Tenon  anesthe-
ia  in  6  cases  (22%),  high  myopia  in  6  cases  (22%),  orbital
racture  in  5  cases  (18.5%),  retinal  detachment  surgery  in  5
ases  (18.5%),  Graves  ophthalmopathy  in  4  cases  (15%),  and
onjunctival  surgery  in  1  case  (4%).
Table  1  shows  pre-treatment  and  post-treatment  patient toxin  for  treatment  of  restrictive  strabismus.  J  Optom.
ata.  All  patients  had  diplopia,  and  33.3%  had  head  turn
t  diagnosis.  The  initial  deviation  was  14  PD  ±  9.9  (range,
--40  PD).  The  mean  number  of  injections  per  patient  was
.6  ±  0.7  (range,  1--3),  and  the  mean  dose  was  9.5  ±  4.8  IU
Pre-treatment
deviation  in  PP
Final  deviation
in  PP
Final  D/T  S/P  Result
10  30  N/Y  Y/N  Bad
5  0  N/N  N/N  Good
18  2  N/N  N/Y  Good
14  0  N/N  N/N  Good
25  16  Y/N  Y/N  Bad
12  4  N/N  N/N  Good
18  33  Y/Y  Y/N  Bad
5  8  Y/N  N/N  Bad
12  8  Y/N  Y/N  Bad
3  12  Y/N  Y/N  Bad
8  4  N/N  N/Y  Good
12  30  Y/N  Y/N  Bad
25  40  Y/N  Y/N  Bad
40  6  Y/N  N/N  Bad
5  0  N/N  N/N  Good
10  16  Y/Y  Y/N  Bad
5  2  N/N  N/N  Good
10  0  N/N  N/N  Good
6  1  N/N  N/N  Good
30  35  Y/Y  Y/N  Bad
8  30  Y/Y  Y/N  Bad
30  25  Y/N  Y/N  Bad
2  8  N/N  N/Y  Good
30  18  Y/N  Y/N  Bad
8  14  Y/N  N/Y  Bad
16  18  Y/N  Y/N  Bad
12  16  Y/N  Y/N  Bad
yopia; GO: Graves ophthalmopathy; Fr: orbital fracture; post RD
ery with sub-Tenon anesthesia; post conj surg: post-conjunctival
: surgery after treatment with botulinum toxin; P: need for prism
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Table  2  Successful  outcome  according  to  type  of  restrictive  strabismus.
Type  of  restrictive  strabismus  Total  (no.  of  cases)  Successful  outcome  (no.  of  cases)  Percentage
High  myopia  6  4  66.66
Orbital fractures  5  3  60
Retinal detachment  surgery 5  2  40
Graves ophthalmopathy 4  0  0
Cataract surgery  6  1  16.66
Conjunctival  surgery  1  0  0
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trange,  2.5--22.5  IU).  One  injection  was  applied  in  55.5%
f  patients  (15/27),  2  injections  in  29.6%  (8/27),  and
 in  14.8%  (4/27).  The  mean  time  from  onset  of  the  symp-
oms  until  the  ﬁrst  injection  was  1.9  ±  1.3  months  (range,
--6  months).  The  ﬁnal  deviation  in  primary  position  was
3.9  ±  12.4  PD  (range,  0--40  PD).  At  the  end  of  follow-up,
9%  of  patients  had  diplopia,  18%  had  head-turn,  52%  needed
urgery  after  botulinum  toxin,  and  14%  needed  treatment
ith  prisms.  Outcome  was  successful  in  10  patients  (37%):  4
igh  myopia  (40%),  3  orbital  fractures  (30%),  2  post-retinal
etachment  surgery  (20%),  and  1  secondary  to  cataract
urgery  with  sub-Tenon  anesthesia  (10%).  Table  2  shows
uccessful  outcome  according  to  the  type  of  restrictive  stra-
ismus.  We  have  not  recorded  any  complications  during
dministration  of  botulinum  toxin.  The  mean  follow-up  was
 years  ±  1.8.
The  small  sample  size  in  each  etiologic  group  did  not
nable  us  to  draw  conclusions  about  the  inﬂuence  of  the
tiology  on  the  outcome  of  treatment.
iscussion
cquired  restrictive  strabismus  can  be  secondary  to  a
eries  of  conditions  including  high  myopia,  Graves  ophthal-
opathy,  orbital  conditions  (fracture,  myositis,  metastasis),
nd  procedures  to  correct  retinal  detachment,  glaucoma,
ataract,  and  conjunctival  disorders.  The  treatment  options
ecommended  to  eliminate  deviation  were  surgery  on  the
xtra-ocular  muscles  and  botulinum  toxin.1--3,6,11 However,
otulinum  toxin  is  not  as  effective  in  restrictive  strabismus
s  in  comitant  strabismus  and  oculomotor  nerve  palsy.  More
njections  and  doses  are  necessary.3 In  our  study,  a  favorable
utcome  was  obtained  in  37%  of  cases,  which  is  lower  than
n  other  types  of  strabismus  such  as  acquired  and  congen-
tal  esotropia  (60--80%),  intermittent  exotropia  (69%),  and
culo-motor  nerve  palsy  (70%).12--15
The  effect  of  botulinum  toxin  depends  on  etiology.  In
ur  sample,  a  favorable  result  was  not  achieved  in  any  of
ases  of  thyroid  strabismus  (2  vertical,  1  horizontal,  and  1
ombined  horizontal  and  vertical)  at  the  end  of  follow-up.
n  every  case,  botulinum  toxin  was  administered  very  early
1  and  2  months  from  the  onset  of  symptoms).  In  3  cases,
0  IU  were  administered,  and  in  1  a  total  of  5  IU.  Lyons  et  al.
obtained  good  results  in  15.78%  of  cases  with  botulinum
oxin,  and  the  deviation  decreased  by  75%,  although  68.42%Please  cite  this  article  in  press  as:  Merino  PS,  et  al.  Botulinum
(2016),  http://dx.doi.org/10.1016/j.optom.2016.09.001
f  patients  needed  strabismus  surgery  after  the  injections.
he  beneﬁt  obtained  with  botulinum  toxin  could  be  associ-
ted  with  the  relaxation  of  the  inﬂammatory  spasm  that  is
haracteristic  of  the  acute  phase  of  the  illness.  Botulinum
i
s
noxin  is  less  effective  in  muscle  ﬁbrosis  and  contracture.5
u  et  al.3 reported  resolution  in  15  of  33  cases  (45.45%)  and
ecreased  deviation  in  12  (36.36%).  Administration  must  be
arly,  with  a  mean  dose  of  8  IU  and  subsequent  injections.
nother  beneﬁt  of  botulinum  toxin  is  the  decrease  in  intra-
cular  pressure  in  primary  position  and  in  supraversion  2--4
onths  after  injection  in  the  inferior  rectus.16,17
At  the  end  of  follow-up,  outcome  was  successful  in
 of  6  cases  (66.66%)  of  strabismus  associated  with  high
yopia.  Treatment  was  applied  early  in  each  case  (within
6  months  after  the  onset  of  symptoms),  and  the  total  dose
as  2.5--17.5  IU.  Few  publications  in  the  literature  ana-
yze  treatment  with  botulinum  toxin  for  acquired  restrictive
trabismus  secondary  to  high  myopia.  The  best  results  are
chieved  in  young  patients  with  poor  binocular  vision  and
evere  amblyopia  because  of  the  neurosensory  adaptation
ollowing  therapy  with  botulinum  toxin.  Botulinum  toxin  has
lso  proven  effective  in  post-surgical  over-correction  and
nder-correction.11,18--20
Botulinum  toxin  is  not  effective  for  restrictive  strabismus
econdary  to  ocular  surgery  for  several  reasons,  includ-
ng  extensive  ﬁbrosis  and  displacement  of  the  superior  and
nferior  oblique  muscles  after  surgery  to  correct  glaucoma
nd  retinal  disorders.  The  frequency  of  successful  outcome
aries  widely  (15--85%).8,21 The  sub-Tenon  anesthesia  used
n  cataract  surgery  is  responsible  for  diplopia  and  restric-
ive  strabismus  secondary  to  muscle  contracture,  ﬁbrosis,
nd  palsy.  Botulinum  toxin  is  effective  in  only  25%  of  cases
f  muscle  palsy,  before  development  of  muscular  ﬁbrosis,
hich  is  frequent  and  has  an  early  onset  in  older  patients.7
n  our  study,  outcome  was  successful  in  40%  (2/5)  of  cases
econdary  to  retinal  surgery,  in  which  botulinum  toxin  was
njected  early  (1--4  months  after  onset  of  symptoms).  Six
ases  were  secondary  to  sub-Tenon  anesthesia  for  cataract
urgery,  although  outcome  was  successful  after  early  injec-
ion  (1  and  2  months  from  the  onset  of  symptoms)  in  only  1
ase  (16.66%).
Restrictive  strabismus  can  be  secondary  to  orbital  condi-
ions  such  as  fractures,  myositis,  neoplasm,  and  metastasis.4
n  our  sample,  outcome  was  successful  in  3  of  5  cases  (60%)
f  orbital  fractures  after  early  treatment  with  botulinum
oxin  (within  <3  months),  with  total  doses  of  5--22.5  IU  and
--3  injections.  Lee  et  al.6 reported  good  results  in  69%  of
atients  with  orbital  conditions,  67%  of  patients  with  myosi-
is,  and  33%  of  patients  with  fractures.  The  beneﬁt  was toxin  for  treatment  of  restrictive  strabismus.  J  Optom.
ndependent  of  the  angle  of  deviation.
Our  study  is  limited  by  its  retrospective  nature  and  the
mall  number  of  patients  in  each  group.  In  addition,  it  was
ot  possible  to  analyze  the  effect  of  etiology  on  outcome.
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Nevertheless,  the  follow-up  period  was  long  enough  to  draw
conclusions  about  the  stability  of  botulinum  toxin  for  treat-
ment  of  acquired  restrictive  strabismus.
In  conclusion,  half  of  the  patients  in  this  sample  had  ver-
tical  deviation.  The  most  frequent  etiology  was  sub-Tenon
anesthesia  for  cataract  surgery  and  high  myopia.  Botulinum
toxin  was  effective  in  only  one-third  of  the  patients  at  the
end  of  follow-up,  and  outcome  was  similar  for  high  myopia,
orbital  fractures  and  retinal  detachment  surgery.  The  results
were  worse  in  cataract  surgery,  and  botulinum  toxin  was  not
effective  in  Graves  opthalmopathy  and  conjunctival  surgery.
Half  of  the  patients  needed  extra-ocular  muscle  surgery
after  treatment  with  botulinum  toxin.  Botulinum  toxin  can
be  considered  a  complementary  or  alternative  approach  to
surgery  in  some  complex  cases  of  acquired  restrictive  stra-
bismus.
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